Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02145039
Other study ID # 2013OC116
Secondary ID MT2013-33C
Status Terminated
Phase N/A
First received
Last updated
Start date October 2014
Est. completion date January 2019

Study information

Verified date December 2019
Source Masonic Cancer Center, University of Minnesota
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen, consisting of fludarabine, cyclophosphamide and low dose total body irradiation (TBI), is designed for the treatment of patients with advanced and/or high risk diseases.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date January 2019
Est. primary completion date January 2018
Accepts healthy volunteers No
Gender All
Age group N/A to 74 Years
Eligibility Inclusion Criteria:

- Must be <75 years old with no 7/8 or 8/8 HLA-matched sibling donor

- One or more potential related mismatched donors (e.g. biologic parent (s) or siblings (full or half) or children). Low resolution using DNA based typing at HLA-A, -B and -DRB1 for potential haploidentical donors is required.

- All diseases listed below are advanced hematologic malignancies not curable by conventional chemotherapy. Responses to conventional treatment range from zero to 30% but are typically short lived.

- Acute Lymphoblastic Leukemia (ALL) in first complete remission (CR1) that is NOT considered favorable-risk.

- Acute Myelogenous Leukemia (AML) in first complete remission (CR1) that is NOT considered as favorable-risk.

- Acute Leukemias in 2nd or subsequent CR

- Biphenotypic/Undifferentiated/Prolymphocytic Leukemias in first or subsequent CR, adult T-cell leukemia/lymphoma in first or subsequent CR

- Burkitt's lymphoma in CR2 or subsequent CR

- Natural killer cell malignancies after response to initial therapy

- Chronic myelogenous leukemia: all types except refractory blast crisis.

- Large-cell lymphoma, Hodgkin lymphoma and multiple myeloma with chemotherapy sensitive disease that has failed or patients who are ineligible for an autologous transplant.

- Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, follicular lymphoma, which have progressed within 12 months of achieving a partial or complete remission.

- Lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia are eligible after initial therapy if chemotherapy sensitive.

- Refractory leukemia or MDS These patients may be taken to transplant in aplasia after induction or re-induction chemotherapy or radiolabeled antibody.

- Bone marrow failure syndromes, except for Fanconi Anemia

- Myeloproliferative syndromes

- Adequate organ function is defined as:

- Cardiac: Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction > 35%. For children that are not able to cooperate with multigated acquisition scan (MUGA) and echocardiography, such should be clearly stated in the physician's note

- Pulmonary: Diffusing capacity of lung for carbon monoxide (DLCO) > 30% predicted, and absence of O2 requirements. For children that are not able to cooperate with pulmonary function tests (PFTs), a pulse oximetry with exercise should be attempted. If nether test can be obtained it should be clearly stated in the physician's note.

- Liver: Transaminases < 5 x upper limit of normal and bilirubin < 3 x upper limit of normal

- Renal: serum creatinine < 2.0 mg/dl (adults) or glomerular filtration rate (GFR) >40 mL/min/1.73m2 (peds). Patients with a creatinine > 1.2 mg/dl or a history of renal dysfunction must have glomerular filtration rate (GFR) > 40 mL/min/1.73m2.

- Adequate performance status is defined as Karnofsky score = 60% (> 16 years of age) or Lansky score = 50 (pediatrics)

- If recent mold infection e.g. Aspergillus - must have minimum of 30 days of appropriate treatment before bone marrow transplant (BMT) and infection controlled and be cleared by Infectious Disease.

- Second BMT: Must be > 3 months after prior myeloablative transplant.

- Patients must be ineligible for autologous transplantation due to prior autologous transplant, an inadequate autologous stem cell harvest, inability to withstand a myeloablative preparative regimen, or clinically aggressive/high risk disease.

- Patients are eligible for transplantation if there is no evidence of progressive disease by imaging modalities or biopsy. Persistent PET activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of CT changes indicating progression.

- Patients with stable disease are eligible for transplantation if the largest residual nodal mass is < 5 cm (approximately). For patients who have responded to preceding therapy, the largest residual mass must represent a 50% reduction and be < 7.5 cm (approximately).

- Voluntary written consent (adult or parental/guardian)

Exclusion Criteria:

- Available and clinically suitable 5-6/6 HLA-A, B, DRB1 matched sibling donor

- Pregnant or breastfeeding

- Evidence of HIV infection or known HIV positive serology

- Current active serious infection

- Unless in post-chemotherapy and radioimmunoconjugated antibody induced aplasia, when he/she would be eligible, patients with acute leukemia in morphologic relapse/ persistent disease defined as > 5% blasts in normocellular bone marrow OR any % blasts if blasts have unique morphologic markers (e.g. Auer rods) or associated cytogenetic markers that allows morphologic relapse to be distinguished are not eligible.

- Chronic myeloid leukemia (CML) in refractory blast crisis

- Large cell lymphoma, mantle cell lymphoma and Hodgkin disease that is progressive on salvage therapy. Stable disease is acceptable to move forward provided it is non-bulky.

- active central nervous system malignancy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fludarabine
Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.
Cyclophosphamide
Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
Radiation:
Total Body Irradiation
TBI 200cGy on day -1 before transplant.
Biological:
Haploidentical stem cell transplant
Non-T-cell depleted bone marrow infusion

Locations

Country Name City State
United States University of Minnesota Masonic Cancer Center Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Masonic Cancer Center, University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary 2 Year Survival Percentage of patients that survive 2 years post-transplant 2 years
Secondary Number of Patients With Hematopoietic Engraftment Engraftment is defined as absolute neutrophil count (ANC) = 5 X 10^8/L for 3 consecutive measurements. 42 days
Secondary Number of Patients With Chimerism Number of patients with chimerism at day 100, 6 months and 1 year 100 days
Secondary Number of Patients Experiencing Acute Graft-versus-host Disease by 100 Days 100 days
Secondary Number of Patients Experiencing Chronic Graft-versus-host Disease by 1 Year 1 year
Secondary Number of Patients Experiencing Transplant Related Mortality (TRM) 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05088356 - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Phase 1
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Completed NCT02592447 - Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) Intervention N/A
Withdrawn NCT04282174 - CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies Phase 2
Terminated NCT01397734 - Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) Phase 1
Withdrawn NCT01011998 - A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML) Phase 2
Completed NCT00975975 - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Phase 2
Completed NCT00378534 - Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants Phase 2
Completed NCT00098033 - Investigation of Clofarabine in Acute Leukemias Phase 2
Terminated NCT00852709 - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias Phase 1
Completed NCT02581007 - Reduced Intensity Conditioning Transplant Using Haploidentical Donors Phase 2
Terminated NCT03547154 - Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026) Phase 2/Phase 3
Terminated NCT02709083 - Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia Phase 2
Terminated NCT02146846 - Population Pharmacokinetics of Imatinib in CML Patients in Iran N/A
Active, not recruiting NCT01036009 - A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies Phase 2
Completed NCT00990587 - Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy Phase 1
Terminated NCT00500006 - A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED) Phase 1
Terminated NCT00594308 - In-Vivo Activated T-Cell Depletion to Prevent GVHD N/A
Completed NCT00493181 - Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients Phase 2
Completed NCT00081926 - Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Phase 4